Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endometrium Clear all
Completed Phase 2 Interventional Results available

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT01210222
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Endometrioid Stromal Sarcoma, Recurrent Uterine Corpus Carcinoma
Interventions
Trebananib
Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Hartford, Connecticut • New Britain, Connecticut • Sarasota, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Early Phase 1 Interventional

Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer

NCT01205672
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimedia Aid Gynecologic Counseling and Consent

NCT03899441
View directory record Official record
Conditions
Endometrium Cancer, Sentinel Lymph Node, Perioperative/Postoperative Complications
Interventions
Video
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Not applicable Interventional

Electro-acupuncture and Assisted Reproductive Technology

NCT01481090
View directory record Official record
Conditions
Infertility
Interventions
Acupuncture, Electro-Acupuncture
Procedure
Lead sponsor
National University of Health Sciences
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Lombard, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional

Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy

NCT02040155
View directory record Official record
Conditions
Cancer of the Cervix, Cancer of the Endometrium
Interventions
Novel nano-scintillator fiber-optic dosimeter (nanoFOD)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women

NCT01877564
View directory record Official record
Conditions
Adenocarcinoma of the Endometrium
Interventions
Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849
View directory record Official record
Conditions
Infertility, Asherman's Syndrome
Interventions
Intrauterine infusion of platelet rich plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 20, 2026, 7:15 AM EDT
Recruiting Not applicable Interventional

Platelet Rich Plasma for Insufficient Endometrium

NCT05538338
View directory record Official record
Conditions
Infertility of Uterine Origin
Interventions
Platelet Rich Plasma Intrauterine infusion, Normal saline Intrauterine infusion
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 2 Interventional

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

NCT01013324
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Neoplasms
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Newport Beach, California • Orlando, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681
View directory record Official record
Conditions
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Interventions
Futibatinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

NCT06253494
View directory record Official record
Conditions
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional

Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma

NCT00595725
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Cervical Carcinoma
Interventions
Lymphatic Mapping
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 20, 2026, 7:15 AM EDT
Completed No phase listed Observational

Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients

NCT00001837
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

NCT00584909
View directory record Official record
Conditions
Uterine Cancer
Interventions
Paclitaxel and carboplatin combination
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

NCT02923349
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01949
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Comparison of Transfers of Fresh and Thawed Embryos in Patients With Prior Failed Embryo Transfer Cycles

NCT00736177
View directory record Official record
Conditions
Infertility, Subfertility
Interventions
Embryo cryopreservation, Fresh embryo transfer
Procedure
Lead sponsor
Fertility Center of Las Vegas
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 20, 2026, 7:15 AM EDT
Withdrawn No phase listed Observational

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

NCT00588263
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Lung Cancer, Melanoma, Non-Hodgkin's Lymphoma, Uterine Cancer, CORPUS UTERI,ENDOMETRIUM, LUNG, OVARY
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 20, 2026, 7:15 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA

NCT01510054
View directory record Official record
Conditions
Controlled Ovarian Stimulation
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 31 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2014
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional

Adaptive Pet Study

NCT01908504
View directory record Official record
Conditions
Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
Interventions
PET-CT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Endometrial Biopsy in Infertile Patients

NCT00064935
View directory record Official record
Conditions
Infertility
Interventions
Endometrial biopsy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
25 Years to 39 Years · Female only
Enrollment
880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
8
States / cities
Birmingham, Alabama • Denver, Colorado • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 3 Interventional

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

NCT02019589
View directory record Official record
Conditions
Secondary Amenorrhea
Interventions
Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
22
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 7:15 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen, Diet, Genetics and Endometrial Cancer

NCT00587886
View directory record Official record
Conditions
Cancer, Endometrial Cancer, Ovarian Cancer, Corpus Uteri, Endometrium
Interventions
Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
1,315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

NCT04774952
View directory record Official record
Conditions
Solid Tumors
Interventions
RMC-5552
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 20, 2026, 7:15 AM EDT